INSMINSMED Inc同业对比
INSMED Inc 与iShares Biotechnology ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:IBB 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INSM本股 | $22.6B#12 | — | 32.0x#9 | 37.2x#11 | 66.7%#1 | -39.7%#13 | -205.6%#13 | -181.1%#12 | -185.1%#11 | 4#3 | -0.9%#13 | — |
| VRTX | $124.5B#4 | 29.1x#6 | 6.4x#4 | 10.4x#8 | 8.9%#7 | 838.1%#2 | 34.8%#2 | 20.4%#6 | 25.4%#3 | — | 4.6%#12 | — |
| GILD | $166.8B#3 | 18.3x#2 | 7.1x#6 | 5.7x#3 | 2.4%#11 | 1672.9%#1 | 34.0%#3 | 36.2%#3 | 21.6%#4 | — | 20.4%#9 | 2.4%#2 |
| AMGN | $212.1B#2 | 27.4x#5 | 23.1x#8 | 5.8x#4 | 10.0%#6 | 88.5%#5 | 24.7%#8 | 83.9%#1 | 15.3%#5 | — | 32.7%#5 | 2.4%#1 |
| REGN | — | 17.0x#1 | — | — | 1.0%#13 | 2.1%#7 | 24.9%#7 | 14.3%#7 | 9.6%#7 | — | 24.6%#8 | — |
| ALNY | $38.3B#7 | 123.9x#10 | 48.5x#10 | 10.3x#7 | 65.2%#2 | 212.8%#3 | 13.5%#9 | 39.8%#2 | — | — | -12.8%#14 | — |
| IQV | $40.7B#6 | 30.3x#7 | 6.5x#5 | 2.5x#1 | 5.9%#9 | -0.9%#10 | 13.4%#10 | 21.9%#5 | 9.1%#8 | — | 27.1%#6 | 1.4%#3 |
| ARGX | $53.9B#5 | — | — | — | — | — | — | — | — | — | 45.5%#4 | — |
| MTD | $28.1B#11 | 32.6x#8 | — | 7.0x#5 | 4.0%#10 | 0.7%#9 | 27.8%#5 | — | 43.8%#1 | 5#2 | 9.8%#10 | — |
| NTRA | $36.1B#9 | — | 20.3x#7 | 15.6x#10 | 35.9%#4 | -9.3%#11 | -13.4%#12 | -11.7%#11 | -18.5%#10 | — | 85.6%#1 | — |
| ONC | $477.2B#1 | 971.2x#11 | 100.3x#11 | 89.3x#12 | 40.2%#3 | 144.5%#4 | 8.4%#11 | 6.0%#9 | 32.7%#2 | 6#1 | 8.0%#11 | — |
| BIIB | $30.4B#10 | 22.2x#4 | 2.1x#1 | 3.1x#2 | 2.2%#12 | -20.8%#12 | 28.7%#4 | 8.7%#8 | 13.0%#6 | 4#3 | 61.2%#3 | — |
| UTHR | $22.2B#13 | 19.3x#3 | 3.8x#3 | 7.0x#6 | 10.6%#5 | 11.7%#6 | 46.9%#1 | 22.6%#4 | — | — | 76.0%#2 | — |
| WAT | $37.7B#8 | 48.9x#9 | 2.5x#2 | 11.9x#9 | 7.0%#8 | 0.8%#8 | 25.4%#6 | 4.2%#10 | 3.5%#9 | 4#3 | 26.6%#7 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-07-29。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议